Vascular endothelial growth factor: much more than an angiogenesis factor
- PMID: 20124007
- PMCID: PMC2814783
- DOI: 10.1091/mbc.e09-07-0591
Vascular endothelial growth factor: much more than an angiogenesis factor
Abstract
Vascular endothelial growth factor (VEGF) is best known as a cytokine essential for embryonic vasculogenesis and for the angiogenesis associated with various pathologies including cancer. However, VEGF also serves other functions that are less widely recognized. An early study (Berse et al., 1992) revealed widespread expression of VEGF transcripts in adult tissues devoid of ongoing neovascularization, thereby predicting additional VEGF functions distinct from angiogenesis. More recent studies have confirmed that VEGF does indeed serve multiple additional functions, including normal maintenance of endothelial and neural cell compartments. These findings have important implications for the use of VEGF antagonists and VEGF receptor antagonists in patients for which inhibition of pathological angiogenesis is the therapeutic goal.
Similar articles
-
Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.Cancer Res. 2004 May 15;64(10):3586-92. doi: 10.1158/0008-5472.CAN-03-2673. Cancer Res. 2004. PMID: 15150116
-
[VEGF, anti-vEGF and diseases].Bull Acad Natl Med. 2008 Feb;192(2):289-300; discussion 300-2. Bull Acad Natl Med. 2008. PMID: 18819684 Review. French.
-
The biology of VEGF and its receptors.Nat Med. 2003 Jun;9(6):669-76. doi: 10.1038/nm0603-669. Nat Med. 2003. PMID: 12778165 Review.
-
Molecular and biological properties of vascular endothelial growth factor.J Mol Med (Berl). 1999 Jul;77(7):527-43. doi: 10.1007/s001099900019. J Mol Med (Berl). 1999. PMID: 10494799 Review.
-
VEGF and PlGF promote adult vasculogenesis by enhancing EPC recruitment and vessel formation at the site of tumor neovascularization.FASEB J. 2006 Jul;20(9):1495-7. doi: 10.1096/fj.05-5137fje. Epub 2006 Jun 5. FASEB J. 2006. PMID: 16754748
Cited by
-
Recent advances of nanotechnology-based tumor vessel-targeting strategies.J Nanobiotechnology. 2021 Dec 20;19(1):435. doi: 10.1186/s12951-021-01190-y. J Nanobiotechnology. 2021. PMID: 34930293 Free PMC article. Review.
-
Macrophage-derived tumor necrosis factor-alpha is an early component of the molecular cascade leading to angiogenesis in response to aortic injury.Arterioscler Thromb Vasc Biol. 2011 May;31(5):1151-9. doi: 10.1161/ATVBAHA.111.223917. Epub 2011 Mar 3. Arterioscler Thromb Vasc Biol. 2011. PMID: 21372301 Free PMC article.
-
The VEGFA-Induced MAPK-AKT/PTEN/TGFβ Signal Pathway Enhances Progression and MDR in Gastric Cancer.Genes (Basel). 2024 Sep 27;15(10):1266. doi: 10.3390/genes15101266. Genes (Basel). 2024. PMID: 39457390 Free PMC article.
-
Relationship of VEGF/VEGFR with immune and cancer cells: staggering or forward?Cancer Biol Med. 2016 Jun;13(2):206-14. doi: 10.20892/j.issn.2095-3941.2015.0070. Cancer Biol Med. 2016. PMID: 27458528 Free PMC article.
-
Homo and Heterotypic Cellular Cross-Talk in Epithelial Ovarian Cancer Impart Pro-Tumorigenic Properties through Differential Activation of the Notch3 Pathway.Cancers (Basel). 2022 Jul 11;14(14):3365. doi: 10.3390/cancers14143365. Cancers (Basel). 2022. PMID: 35884426 Free PMC article.
References
-
- Baffert F., Le T., Sennino B., Thurston G., Kuo C. J., Hu-Lowe D., McDonald D. M. Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling. Am. J. Physiol. 2006;290:H547–H559. - PubMed
-
- Broeders M. A., Tangelder G. J., Slaaf D. W., Reneman R. S., oude Egbrink M. G. Endogenous nitric oxide protects against thromboembolism in venules but not in arterioles. Arteriosc. Thromb. Vasc. Biol. 1998;18:139–145. - PubMed
-
- D'Amore P. A. Modes of FGF release in vivo and in vitro. Cancer Metastasis Rev. 1990;9:227–238. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources